Update: Self-administered Saphnelo remains under FDA review in the U.S.

The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC), self-administration of Saphnelo (anifrolumab).

This post was originally published on this site